Tekcapital PLC (LON:TEK) said its portfolio company, medical treatment developer Belluscura PLC, has widened its portfolio with several new patent filings in patient recovery.
The AIM-listed investment firm, which helps commercialise university tech, said Belluscura and its research partner Separation Design Group had filed three patent applications and received a Notice of Allowance for a fourth application in the fields of respiratory, postoperative recovery, sleep monitoring and artificial intelligence (AI).
READ: Tekcapital's blue-chip hires
The latest application involves the use of AI and deep learning technology in combination with Belluscura’s oxygen enrichment and sleep technology to improve patient recovery after operations and reduce readmissions.
The new filings will take Belluscura’s total licenses in the fields to 15 patents and applications.
Bob Rauker, chief executive of Belluscura, said the incorporation of AI into the firm’s oxygen-enrichment technology opened up “additional markets in postoperative recovery”, beyond the rapidly growing US$1.2bn portable oxygen concentrator market.
In mid-morning trading, Tekcapital shares were up 2.9% at 8.7p.
--Adds share price--